Patent News. We publish all the latest insights about patents and patent cases and ways to make profits from trading/investing in these up and coming companies.
Feel free to contact with any questions.
We await your reply.
We are a group of sophisticated investors with experience in patent litigation, experimental economics, corporate finance and responsible corporate governance. Our member’s comments are carried online by publications such as The Wallstreet Journal, Reuters, CNN, Seeking Alpha and Motley Fool.
PatentPlay realtime member editorials are broadcast by Rallythevote.com.
Patentplays™ is a Trademark with Pending US Registration, all rights reserved.
Long time biotech and tech investor who enjoys discussing stocks, options, and sharing ideas freely.
Investors buy or sell at their own risk. All my articles strictly represent an 'opinion' and in no-way should be construed as individual investor advice.
I am part of a small investment group that combines significant business experience in product marketing and communications with legal analysis and interpretation. My partners and I combine for over 50 years of experience in these fields.
I am an active husband, father, lawyer (more than 24 years, how time flies), and investor. I believe in contrarian investing, i.e., going where the crowd isn't. I believe that successful investing, like successful living, requires equal parts listening and evaluating, followed by independent decision making.
I have been in the market since 1981. I have set international records in option trading contests, as well as lost a few fortunes of my own while trading. I have written many articles for trading magazines both on and offline and have been featured in a Large Metro Daily.
It really means crap though, unless you can make an Amazing Living as a Trader. Not getting by as a Trader, but makin' it; Big-time... That's where I come in.
My main interests are in technical analysis of stock movements and option strategies. I have even designed a (Free) covered call excel sheet that traders use to define the best covered call strategy for themselves and/or their clients.
You will find me at my computer constantly pouring over stock charts of various timeframes against various technical analysis tools that I use. I also monitor what "the crowd" watches so I can be comfortably ahead of them, as usual.
I also do a mean Christopher Walken impersonation of him doing technical analysis of companies and their charts: http://stocktwits.com/WalkenTalken
I have been a technology investor for over twenty-five years. My investing style includes a combination of Fundamental Analysis with Technical Analysis used for entry and exit points. I have followed several stocks involved in patent litigations including Rambus (RMBS), Interdigital (IDCC), Tessera (TSRA) and Star Scientific (STSI). I follow the actual trials, read the transcripts and the briefs and attempt to handicap the outcomes. I attend various hearings, trials, and oral arguments whenever possible, including appeals to the CAFC, and occasionally attend hearings/trials at various District Courts and the ITC. I have attended over 30 oral arguments at the CAFC and I have a good feel for the various judges.
Star Scientific (STSI) is my favorite stock for 2014. STSI has transformed themselves from a tobacco company to a Biopharma company in 2012 and 2013, and this year we will see the true value of the company now that scientific researchers are running the company. Star Scientific will also probably be changing their name in 2014, and may choose to become known as Rock Creek Pharmaceuticals (their division that produces Anatabloc). Although STSI has exited the tobacco manufacturing business (and settled with RJR for a paltry $5 Million), they still own key tobacco curing patents that have been validated by both the USPTO and the CAFC, and these patents don't expire until 2018. Star's new TSNA BDL patent (granted in 2012 by the USPTO) doesn't expire until 2030. I expect STSI (Rock Creek) to have a banner year in 2014 as the world starts to learn the miraculous ability of Anatabloc to treat a variety of auto immune diseases and other conditions associated with NF-kB inflammation (including MS, Rheumatoid Arthritis, Asthma, Crohn's, Parkinson's, Traumatic Brain Injury, Alzheimer's, and various types of cancer, etc). Rock Creek Pharmaceuticals should have more and more peer reviewed medical journal articles on the efficacy of Anatabloc coming out in 2014. I also expect that Rock Creek will file several drug applications (IND's) with the FDA in 2014. In addition, I expect Rock Creek Pharmaceuticals to team or partner with one or more Big Pharma companies for various human ailments as they pursue these IND's. For all these reasons, I expect Star Scientific to be at least a $10 stock before the end of the 2014, and possibly much higher than that.
M.E. Garza is one of the founders of the biotech and healthcare sector news portal BioMedReports.com. He believes in getting the news from credible sources on the street and often reaches out to CEOs and newsmakers directly for interviews and discussions about their companies. Since he began publishing in 2008, Garza has built a reputation as a writer and reporter who can move markets. His track record for accurately reporting rumors and alerting readers about developments in the biotech/healthcare sector is unmatched during that time.
Dr. John L. Faessel is a seasoned and respected Wall Street professional with industry-wide recognition for expertise in market strategy and analysis. He is widely recognized for his insights in public companies. For over 20-years Dr. Faessel’s ON THE MARKET reports have been widely distributed to a throughout the world to an extensive list of financial institutions, investment banking firms, brokers, foundations, mutual funds, hedge funds and private high net worth investors. Dr. Faessel is also a daily contributor to the widely read JagNotes.com, Wall Streets oldest daily rag.